The biopharmaceutical industry faces persistent misinformation campaigns targeting patent practices, with myths about patent thickets, evergreening, and excessive patent filings driving misguided policy proposals. This session presents evidence-based analysis directly contradicting these narratives using USPTO data, empirical research, and economic studies. Panelists will examine how organizations propagate flawed methodologies that inflate patent counts by including abandoned applications and non-Orange Book patents, creating misleading impressions of the patent landscape. Distinguished experts from industry, law firms, and global jurisdictions will demonstrate how robust patent protection enables both innovation incentives and timely generic competition, while debunking claims that follow-on innovations represent trivial evergreening. Attendees will gain crucial insights into defending evidence-based patent policy against activist narratives threatening the innovation ecosystem that has made America the global leader in biopharmaceutical R&D.